Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
headphones
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast

PVI, PeerView Institute for Medical Education

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
bookmark
Share icon

All episodes

Best episodes

Top 10 PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast Episodes

Goodpods has curated a list of the 10 best PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast episode by adding your comments to the episode page.

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast - J. Sloan Manning, MD - Overcoming Disparities in the Accurate Diagnosis and Optimal Management of MDD in Rural America
play

08/27/18 • 38 min

Overcoming Disparities in the Accurate Diagnosis and Optimal Management of MDD in Rural America
bookmark
plus icon
share episode
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast - Michael Polydefkis, MD - Clinical Pearls for the Accurate Diagnosis and Optimal Treatment of Hereditary ATTR Amyloidosis
play

07/31/19 • 21 min

Go online to PeerView.com/HMV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert neurologist shares clinical pearls for accurately diagnosing and optimally treating patients with hereditary ATTR amyloidosis. Upon completion of this activity, participants should be better able to: Describe the common symptoms and underlying genetic mechanisms of hereditary ATTR amyloidosis, Apply genetic testing methods to accurately diagnose hereditary ATTR amyloidosis, Cite recent efficacy and safety data about available therapies for the management of hereditary ATTR amyloidosis, Employ approved therapies to reduce hospitalizations and mortality in patients with hereditary ATTR amyloidosis.
bookmark
plus icon
share episode
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast - Karl E. Anderson, MD - Acute Hepatic Porphyria: Disease Diagnosis and Revelations Regarding the Role of siRNA Therapy
play

06/02/21 • 31 min

Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.
bookmark
plus icon
share episode
Go online to PeerView.com/SPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The latest stroke statistics estimate that about 800,000 individuals in the United States experience a stroke each year. Furthermore, about 20% of all strokes are recurrent, and many of these patients previously experienced a minor stroke or transient ischemic attack (TIA). Recurrence is greatest within the first 24 to 48 hours, but the risk remains elevated for months, even years, after the initial event. The American Heart Association (AHA) and American Stroke Association (ASA) recently updated their guidelines for stroke prevention to include expanded and detailed recommendations for the use of dual antiplatelet therapy (DAPT), the combination of aspirin and clopidogrel or ticagrelor, to further reduce the risk of stroke. These guidelines also include specific recommendations for individuals with minor acute ischemic stroke (AIS) or a TIA. In this activity based on a recent satellite symposium in New Orleans, leading experts on stroke management highlight the current guideline recommendations and discuss the latest perspectives on DAPT before transitioning to patient case scenarios where each expert demonstrates how these advances can be translated into clinical practice to improve outcomes and reduce the risk of recurrent stroke, while accounting for bleeding risks, antiplatelet resistance, and patient adherence. Upon completion of this CE activity, participants will be able to: Identify individuals with AIS or TIA who are appropriate candidates for treatment with antiplatelet therapy to reduce the risk of recurrent stroke, Assess the benefits and risks of using P2Y12 inhibitors with aspirin as DAPT for the prevention of recurrent stroke, Apply DAPT with P2Y12 inhibitors in appropriate patients following symptom onset to reduce the risk of recurrent stroke, Employ patient-centered communication strategies to facilitate adherence to DAPT with P2Y12 inhibitors in appropriate patients with AIS or TIA to reduce the risk of recurrent stroke.
bookmark
plus icon
share episode
Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient’s disease activity, treatment preferences and goals, and therapeutic options.
bookmark
plus icon
share episode
Go online to PeerView.com/ZTU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert will review the pathophysiology and clinical heterogeneity of Fabry disease. With an emphasis on accurate, early diagnosis and timely treatment, the activity will test learners’ knowledge about current and emerging therapeutic options for patients with Fabry disease. Upon completion of this activity, participants should be better able to: Recognize the pathophysiology, signs and symptoms, clinical manifestations, and consequences of FD; Apply evidence-based tools, technologies, and strategies to diagnose individuals with FD in a timely manner; and Integrate current and emerging options into the treatment regimens, as appropriate, for patients with FD, taking into account the latest efficacy and safety data from recent clinical trials.
bookmark
plus icon
share episode
Go online to PeerView.com/EQK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a live symposium recently held in West Palm Beach, Florida, leading experts on multiple sclerosis (MS) dive into the latest data on approved and emerging therapies for relapsing and progressive forms of MS and offer practical strategies to improve patient management, treatment selection, and outcomes. In addition to exploring the treatment armamentarium for MS, the panel considers the prognostic and predictive utility of serum neurofilament light chain as an emerging biomarker, including how it may affect disease-modifying treatment selection and sequencing. Upon completion of this activity, participants should be better able to: Apply current data on approved and emerging disease-modifying therapies for the treatment of relapsing forms of MS, Employ recent data related to available and investigational therapies for the treatment of progressive forms of MS, Assess available data on the potential prognostic and predictive utility of serum neurofilament light chain levels in patients with MS, Develop strategies based on clinical phenotypes, goals, preferences, and potential biomarker findings when selecting disease-modifying therapies for patients with MS.
bookmark
plus icon
share episode
Go online to PeerView.com/SDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric neurology uses a novel, interactive talk to guide learners through the diagnosis and presymptomatic treatment of spinal muscular atrophy (SMA). Upon completion of this activity, participants should be better able to: Identify the important role of newborn screening in the presymptomatic treatment of spinal muscular atrophy, Cite available data on approved therapies for the treatment of spinal muscular atrophy, including presymptomatic patients, Apply approved therapies in presymptomatic patients with spinal muscular atrophy
bookmark
plus icon
share episode
Go online to PeerView.com/DRB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The advent of the fourth treatment modality, tumor treating fields (TTFields), and ongoing research on novel systemic agents are continuing to improve clinical outcomes for patients with glioblastoma. In this activity, based on a recent live symposium planned in collaboration with the American Brain Tumor Association and held during the 24th Annual Meeting of the Society for Neuro-Oncology, neuro-oncology experts discuss cutting-edge advancements with TTFields therapy and the future outlook on novel targeted agents for patients with glioblastoma. Additionally, the faculty share stories about real patients to highlight how scientific advancements and clinical data translate into personalized care. Upon completion of this activity, participants should be better able to: Summarize the biologic rationale of TTFields, immunotherapy, multikinase and TRK inhibitors, among other drug classes for the treatment of glioblastoma, Assess the latest clinical evidence on currently available treatment strategies, such as TTFields and targeted TRK inhibitors, for newly diagnosed and recurrent glioblastoma, Review recent safety and efficacy evidence on novel agents under investigation, including immune checkpoint and multikinase inhibitors, for the therapeutic management of glioblastoma, Develop personalized treatment plans for patients with glioblastoma (both newly diagnosed and recurrent), including the consideration of enrolling in clinical trials
bookmark
plus icon
share episode
Taking Stock of Late-Breaking Data on Disease-Modifying Therapies for Multiple Sclerosis: What Are the Key Learnings From Berlin?
bookmark
plus icon
share episode

Show more best episodes

Toggle view more icon

FAQ

How many episodes does PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast have?

PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast currently has 154 episodes available.

What topics does PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast cover?

The podcast is about Health & Fitness, Neuroscience, Cme, Medicine, Neurology, Podcasts, Science, Medical Education and Psychiatry.

What is the most popular episode on PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast?

The episode title '"Brenda L. Banwell, MD, FAAP, FRCPC, FAAN - Addressing Barriers to the Ready Recognition and Timely Treatment of Pediatric Multiple Sclerosis"' is the most popular.

What is the average episode length on PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast?

The average episode length on PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast is 45 minutes.

How often are episodes of PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast released?

Episodes of PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast are typically released every 9 days.

When was the first episode of PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast?

The first episode of PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast was released on Aug 27, 2018.

Show more FAQ

Toggle view more icon

Comments